Baird Financial Group
CAPR icon

Baird Financial Group’s Capricor Therapeutics CAPR Stock Holding History

Baird Financial Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,330
Closed -$54K – 1239
2015
Q3 		$54K Buy
+1,330
New +$59.2K ﹤0.01% 1226

Other funds holding CAPR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Baird Financial Group's CAPR Position: Q4 2015 in Review

Baird Financial Group sold out of Capricor Therapeutics (CAPR) in Q4 2015, closing a stake of 1,330 shares — an estimated $54K sold.

Baird Financial Group first reported a position in CAPR in Q3 2015 and held it in 1 quarter. The position peaked at $54K in Q3 2015. 18 funds tracked by Wall St. Rank hold CAPR as of Q4 2015.

  • Baird Financial Group reported no remaining Capricor Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Baird Financial Group sold 1,330 Capricor Therapeutics shares in Q4 2015, an estimated $54K.
  • Baird Financial Group first reported a position in Capricor Therapeutics in Q3 2015 and held it in 1 quarter.
  • Baird Financial Group's Capricor Therapeutics position peaked at $54K in Q3 2015.
  • 18 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2015.

Based on Baird Financial Group's 13F filing for Q4 2015, filed 11 Feb 2016.